| 000 | 01923 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514163106.0 | ||
| 264 | 0 | _c20040126 | |
| 008 | 200401s 0 0 eng d | ||
| 022 | _a0003-4967 | ||
| 024 | 7 |
_a10.1136/ard.2003.009563 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan de Putte, L B A | |
| 245 | 0 | 0 |
_aEfficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. _h[electronic resource] |
| 260 |
_bAnnals of the rheumatic diseases _cDec 2003 |
||
| 300 |
_a1168-77 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aRau, R | |
| 700 | 1 | _aBreedveld, F C | |
| 700 | 1 | _aKalden, J R | |
| 700 | 1 | _aMalaise, M G | |
| 700 | 1 | _avan Riel, P L C M | |
| 700 | 1 | _aSchattenkirchner, M | |
| 700 | 1 | _aEmery, P | |
| 700 | 1 | _aBurmester, G R | |
| 700 | 1 | _aZeidler, H | |
| 700 | 1 | _aMoutsopoulos, H M | |
| 700 | 1 | _aBeck, K | |
| 700 | 1 | _aKupper, H | |
| 773 | 0 |
_tAnnals of the rheumatic diseases _gvol. 62 _gno. 12 _gp. 1168-77 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/ard.2003.009563 _zAvailable from publisher's website |
| 999 |
_c14379534 _d14379534 |
||